

Global BCL-2 (B Cell Lymphoma 2) Inhibitors Market & Clinical Trials Insight 2025

<https://marketpublishers.com/r/G223B524E3EEEN.html>

Date: February 2021

Pages: 0

Price: US\$ 2,400.00 (Single User License)

ID: G223B524E3EEEN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

'Global BCL-2 (B Cell Lymphoma 2) Inhibitors Market & Clinical Trials Insight 2025'
Report Highlights:

Global BCL-2 Inhibitors Market Opportunity: >US\$ 4 Billion by 2025

Insight on Market Indicators & Approved Drugs Sales Data

Global BCL-2 Inhibitors Market Absolute Growth: >300% (97% CAGR, 2018 - 2020)

Comprehensive Information On Ongoing Clinical Trials

Global BCL-2 inhibitors Clinical Trials By Company, Indication & Phase

Venetoclax Is The First Approved Drug Belonging To The Class Of BCL2 Inhibitor

The strategy opted by the Bcl2 inhibitor market and variety of drugs under clinical development are considered to be important steps in changing the overall therapeutic approach for the cancer treatment. The global Bcl2 inhibitor market is categorized as a well-designed, carefully controlled therapeutic market that targets the Bcl2 protein for killing the cancer cells. In addition, the Bcl2 inhibitor drug market appears to be appropriate market in combination with novel immunotherapy drugs and

chemotherapeutic drugs in order to alter the development and progression phase of different cancer types, which when avoided could lead to creation of toxic substances and eventually death of the patient. The market since its development in the cancer therapeutics market has confirmed hundreds of advantages over the other developed current standard therapies.

The total volume of the agents available in the market has gradually increased by a certain amount of percentage and it is witnessed that the market has modestly moved faster in terms of size than any other cancer therapies, which altogether is driven by millions of factors around the world. There has been a substantial increase in the spending of the medicine, which is primarily driven by acceptance of the therapy by the developed markets and increased percentage of pharmerging markets. All the developed markets focused towards the inhibitor therapy have offset increased the production rate as well as commercialization strategies in order to end the struggle of the patients who have not been responding to any other cancer therapies available in the market.

In the past few years, the number of Bcl2 inhibitor drugs that have reached the last stage of the development pipeline is witnessed to gradually impact the current growth rate of overall market. The arrival of novel drugs and expected arrival of novel active substances in the market are estimated to address significant unmet needs of the cancer patients across the globe. In addition to this, the global continued research with respect to the existing mechanism of action of drugs is estimated to cross the spectrum of a well-define market towards a market that is huge and unavoidable.

The global development of the market in different research centers and bio-pharmaceutical companies is estimated to challenge the current traditional cancer therapies. The market on a brighter side involves complete novel platform that is making the cancer patients observe high overall survival rate, five-year survival years, complete response and progression free survival. Also, association of the market with gene-editing technology such as CRISPR and technologically driven method artificial intelligence are estimated to transform the market by creating a plethora of medical applications. Healthcare advances delivered by the market are expected to treat a wide range of cancer types as well as provide the outcomes that were significantly required by the cancer patients for a long period of time.

Compared to few decades ago with the start of the blooming market, the therapy has observed some real CAGR growth rate progression in different pharmaceutical markets of the world. At global level, the spending for conducting clinical research activities at

different sites has increased to huge percentage over the past few years in some of the major pharmaceutical market and is estimated to grow more. Volume of the drugs available in the pharmaceutical markets has also grown to a certain amount over the past few years and is expected to grow more in the upcoming years. Broad applications of the market towards cancer patients have led to the range of clinical research activities and other strategies arrival that have helped the market to restart and structure the unstructured cancer therapy market. Overall growth of the volume of the drugs available in the market is estimated to be driven by the non-beneficial approval of drugs under other markets that account for majority of the cancer market, as well as the outlook of the healthcare benefits.

Contents

1. INTRODUCTION TO B CELL LYMPHOMA-2 (BCL2) INHIBITORS

- 1.1 Overview
- 1.2 Evolution of BCL2 Inhibitors

2. BCL2 INHIBITORS - MECHANISM OF ACTION

3. ROLE OF BCL2 INHIBITORS IN CANCER MANAGEMENT

4. BCL2 INHIBITORS IN HEMATOLOGICAL CANCERS

- 4.1 Overview
- 4.2 Impact of BCL2 Inhibitors by Type of Hematological Cancer
 - 4.2.1 BCL2 Inhibitors for Acute Myeloid Leukemia (AML) & Chronic Myeloid Leukemia (CML)
 - 4.2.2 BCL2 Inhibitors in Acute Lymphocytic leukemia (ALL) & Chronic Lymphocytic Leukemia (CLL)
 - 4.2.3 BCL2 Inhibitors in Lymphoma & Multiple Myeloma
- 4.3 Ongoing Research & Development
 - 4.3.1 AZD4320
 - 4.3.2 S65487 (VOB560)
 - 4.3.3 APG-2575
 - 4.3.4 S55746 (BCL 201)
 - 4.3.5 LP-108
 - 4.3.6 BGB-11417

5. BCL2 INHIBITORS IN LUNG CANCERS

- 5.1 Potential of BCL2 Inhibitors as Lung Cancer Therapeutics
- 5.2 Current Research & Advancements
 - 5.2.1 Venetoclax
 - 5.2.2 Navitoclax
 - 5.2.3 APG-1252
 - 5.2.4 AT-101

6. BCL2 INHIBITORS IN OTHER CANCERS

6.1 Role of BCL2 Inhibitors in Breast Cancer

6.2 BCL2 Inhibitors for Ovarian Cancer

7. GLOBAL BCL-2 INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

7.1 Research

7.2 Preclinical

7.3 Phase-I

7.4 Phase-I/II

7.5 Phase-II

7.6 Phase-III

7.7 Registered

8. MARKETED BCL-2 INHIBITOR DRUG CLINICAL INSIGHT: VENETOCLAX (VENCLYXTO)

9. GLOBAL BCL2 INHIBITOR MARKET ANALYSIS

9.1 Market Overview

9.2 Current Market Scenario

10. BCL2 INHIBITORS MARKET REGIONAL SEGMENTATION

10.1 US

10.2 Europe - Market Opportunity

10.3 Japan

10.4 China

10.5 Australia

11. COMMERCIALY AVAILABLE BCL2 INHIBITOR DRUG: VENCLEXTA

11.1 Dosage & Patent Insight

11.2 Price Analysis

11.3 Sales Analysis

12. BCL2 INHIBITORS MARKET CLINICAL INSIGHT

12.1 By Phase

12.2 By Status

12.3 By Indication

13. GLOBAL BCL2 INHIBITORS MARKET DYNAMICS

13.1 Driving Factors for BCL2 Inhibitors Market

13.2 Challenges for BCL2 Inhibitors Market

14. GLOBAL BCL2 INHIBITORS MARKET FUTURE OUTLOOK

15. COMPETITIVE LANDSCAPE

15.1 Abbvie

15.2 Amgen

15.3 Novartis

15.4 Roche

15.5 AstraZeneca

15.6 Ascentage Pharma

15.7 BeiGene

15.8 Ligand Pharma

15.9 Tocris Bioscience

List Of Figures

LIST OF FIGURES

Figure 1-1: Evolution of BCL2 Inhibitors in Late 20th Century

Figure 1-2: Evolution of BCL2 Inhibitors in Early 21st Century

Figure 2-1: BCL2 Family Genes By Type

Figure 2-2: General Mechanism of BCL2 Inhibitors for Preventing Mitochondria Outer Membrane Permeabilization (MOMP)

Figure 2-3: BCL2 Inhibitors – Mechanism of Action

Figure 2-4: Anticancer Mechanism of Venetoclax

Figure 3-1: Global – BCL2 Expression by Type of Cancer (%), 2020

Figure 4-1: Global – Newly Diagnosed Cases by Leading Types of Hematological Cancer, 2020

Figure 4-2: Global – Number of Deaths by Leading Types of Hematological Cancer, 2020

Figure 4-3: BCL2 Genes Expressed Over AML Cells

Figure 4-4: Factors Governing Levels of BCL2 over ALL Cells

Figure 4-5: Investigational BCL2 Inhibitors for Hematological Cancers

Figure 4-6: AZD4320 Phase I Trial – Study Initiation & Expected Completion Year

Figure 4-7: S65487 Phase I Trial – Study Initiation & Expected Completion Year

Figure 4-8: S65487/ MIK665 Combinational Phase I Trial – Study Initiation & Expected Completion Year

Figure 4-9: APG-2575/Rituximab/Ibrutinib Combinational Phase I-II Trial – Study Initiation & Expected Completion Year

Figure 4-10: APG-2575/Lenalidomide/Dexamethasone Combinational Phase I-II Trial – Study Initiation & Expected Completion Year

Figure 4-11: APG-2575/ APG-115 Combinational Phase I Trial – Study Initiation & Expected Completion Year

Figure 4-12: Lp-108 Phase I Trial for CML/AML – Study Initiation & Expected Completion Year

Figure 4-13: LP-108 Phase I Trial for Lymphoma & CLL – Study Initiation & Expected Completion Year

Figure 4-14: BGB-11417 Phase Ia Trial – Study Initiation & Expected Completion Year

Figure 5-1: Global – Number of Newly Diagnosed Lung Cancer Cases (Million), 2020, 2025 & 2030

Figure 5-2: Global – Number of Newly Diagnosed Lung Cancer Cases (Million)

Figure 5-3: Investigational BCL2 Inhibitors for Lung Cancers

Figure 5-4: Venetoclax/Irinotecan Phase I-II Trial for SCLC – Study Initiation & Expected

Completion Year

Figure 5-5: Roche's Venetoclax Phase I Combinational Trial for SCLC – Study Initiation & Expected Completion Year

Figure 5-6: AbbVie's Venetoclax Phase I Combinational Trial for SCLC – Study Initiation & Expected Completion Year

Figure 5-7: Navitoclax/Vistusertib Phase I-II Combinational Trial for SCLC – Study Initiation & Expected Completion Year

Figure 5-8: Navitoclax/ Osimertinib Phase I Combinational Trial for NSCLC – Study Initiation & Expected Completion Year

Figure 5-9: APG-1252/ Paclitaxel Phase I-II Combinational Trial – Study Initiation & Expected Completion Year

Figure 5-10: APG-1252 Phase I Monotherapy Trial – Study Initiation & Expected Completion Year

Figure 5-11: APG-1252/ Osimertinib Mesylate Phase Ib Combinational Trial – Study Initiation & Expected Completion Year

Figure 6-1: Global – Number of Newly Diagnosed Breast Cancer Cases (Million), 2020, 2025 & 2030

Figure 6-2: Global – Number of Newly Diagnosed Breast Cancer Cases (Million), 2020, 2025 & 2030

Figure 6-3: Global – Number of Newly Diagnosed Ovarian Cancer Cases & Deaths, 2020

Figure 9-1: Global – Number of Newly Diagnosed Cancer Cases (Million), 2020, 2025 & 2030

Figure 9-2: Global – Number of Cancer Deaths (Million), 2020, 2025 & 2030

Figure 9-3: Global – Share of BCL2 Inhibitors Market in Total Leukemia Drugs Market (US\$ Billion), 2020

Figure 9-4: Global – Leukemia Drugs Market by Drug Type (%), 2020

Figure 9-5: Global – Leukemia Drug Market Size (US\$ Billion), 2020 - 2025

Figure 9-6: Global – Cancer Drug Market Size (US\$ Billion), 2020 - 2025

Figure 9-7: Global – BCL2 Inhibitors Market Size (US\$ Million), 2018 - 2020

Figure 9-8: Global – BCL2 Inhibitors Market Size (US\$ Billion), 2020 - 2025

Figure 9-9: Global – BCL2 Inhibitors Market by Region (US\$ Million), 2020

Figure 9-10: Global – BCL2 Inhibitors Market by Region (%), 2020

Figure 10-1: US – Number of Newly Diagnosed Cancer Cases (Million), 2020, 2025 & 2030

Figure 10-2: US – Number of Cancer Deaths, 2020, 2025 & 2030

Figure 10-3: US – BCL2 Inhibitors Market Size (US\$ Million), 2018 - 2020

Figure 10-4: US – BCL2 Inhibitors Market Size (US\$ Million), 2020 - 2025

Figure 10-5: Europe – Number of Newly Diagnosed Cancer Cases (Million), 2020, 2025

& 2030

Figure 10-6: Europe – Number of Cancer Deaths, 2020, 2025 & 2030

Figure 10-7: Japan – Number of Newly Diagnosed Cancer Cases, 2020, 2025 & 2030

Figure 10-8: Japan – Number of Cancer Deaths, 2020, 2025 & 2030

Figure 10-9: Japan – Cancer Drug Market Opportunity (US\$ Billion), 2020 - 2025

Figure 10-10: China – Number of Newly Diagnosed Cancer Cases (Million), 2020, 2025 & 2030

Figure 10-11: China – Number of Cancer Deaths (Million), 2020, 2025 & 2030

Figure 10-12: China – Cancer Drug Market Opportunity (US\$ Billion), 2020 - 2025

Figure 10-13: Australia – Number of Newly Diagnosed Cancer Cases 2020, 2025 & 2030

Figure 10-14: Australia – Number of Cancer Deaths, 2020, 2025 & 2030

Figure 11-1: Venclexta – Approval Year by Region

Figure 11-2: Venclexta – FDA Approval Year by Indication

Figure 11-3: US - Venetoclax Patent Issue & Expiration year

Figure 11-4: Venetoclax Monotherapy – Recommended Dose by Treatment Week for CLL Management (mg/day)

Figure 11-5: Venetoclax Combinational – Recommended Dose in Initial & Subsequent Treatment Cycle for CLL (mg/Cycle)

Figure 11-6: Venetoclax Monotherapy – Recommended Dose for AML (mg/day)

Figure 11-7: Venclexta – Price for 2 Tablet Supply & Price Per Unit Tablet of 10mg (US\$), January'2021

Figure 11-8: Venclexta – Price for 14 Tablet Supply & Price Per Unit Tablet of 10mg (US\$), January'2021

Figure 11-9: Venclexta – Price for Various Supplies of 50mg Tablet (US\$), January'2021

Figure 11-10: Venclexta – Price for 120 Tablet Supply & Price Per Unit Tablet of 100mg (US\$), January'2021

Figure 11-11: Venclexta – Price for 180 Tablet Supply & Price Per Unit Tablet of 100mg (US\$), January'2021

Figure 11-12: Venclexta – Price for 42 Kit & Price Per Unit Kit (US\$), January'2021

Figure 11-13: Global - Venclexta Annual Sales Value (US\$ Million), 2018 - 2020

Figure 11-14: US - Venclexta Annual Sales Value (US\$ Million), 2018 - 2020

Figure 11-15: Venclexta - Annual Sales Value by Region (US\$ Million), 2019

Figure 11-16: Venclexta – Annual Sales Value by Region (%), 2019

Figure 11-17: Global - Venclexta Quarterly Sales Value (US\$ Million), 2019

Figure 11-18: US - Venclexta Quarterly Sales Value (US\$ Million), 2019

Figure 11-19: Global - Venclexta Quarterly Sales Value (US\$ Million), 2020

Figure 11-20: US - Venclexta Quarterly Sales Value (US\$ Million), 2020

Figure 11-21: Global - Venclexta Sales Value by Region (US\$ Million), 2020
Figure 11-22: Global - Venclexta Sales Value by Region (%), 2020
Figure 12-1: Global – Number of BCL2 Inhibitors Related Clinical Trials, February'2021
Figure 12-2: Global – Number of BCL2 Inhibitors Related Clinical Trials, February'2021
Figure 12-3: Global – Number of BCL2 Inhibitors Related Clinical Trials, February'2021
Figure 12-4: Global – Number of BCL2 Inhibitors Related Clinical Trials, February'2021
Figure 12-5: Global – Number of BCL2 Inhibitors Related Clinical Trials, February'2021
Figure 12-6: Global – Number of BCL2 Inhibitors Related Clinical Trials, February'2021
Figure 13-1: BCL2 Inhibitors Market Drivers
Figure 13-2: Challenges for BCL2 Inhibitors Market
Figure 13-3: US – Treatment Cost Comparison for Leukemia by Drugs (US\$),
January'2021

I would like to order

Product name: Global BCL-2 (B Cell Lymphoma 2) Inhibitors Market & Clinical Trials Insight 2025

Product link: <https://marketpublishers.com/r/G223B524E3EEEN.html>

Price: US\$ 2,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G223B524E3EEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970